Evidence map›Paper›PMID 37777160›Full record

ReviewPharmacology & therapeutics2023

Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases.

Pengfei Xu, Xinran Cai, Xiuchen Guan, Wen Xie

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Pengfei XuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430072, China.
Xinran CaiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Xiuchen GuanDepartment of Orthodontics, School of Stomatology, Capital Medical University, Beijing 100069, China.
Wen XieCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA. Electronic address: wex6@pitt.edu.
University of Pittsburgh · USCapital Medical University · CN

Funding

Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and MorbidityR35ES030429 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Wen Xie · 2019 to 2026
$6.9M
Cellular and Metabolic Basis of the Role of CYP1B1 in Liver FibrosisR01DK135538 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Wen Xie · 2023 to 2026
$1.6M
PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic ShockR01DK117370 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, WEN · 2019 to 2022
$1.4M
NIDDK NIH HHS R01 DK117370NIDDK NIH HHS R01 DK135538NIEHS NIH HHS R35 ES030429
6 · The paper itself

Abstract

Protein sulfoconjugation, or sulfation, represents a critical post-translational modification (PTM) process that involves the attachment of sulfate groups to various positions of substrates within the protein peptides or glycoproteins. This process plays a dynamic and complex role in many physiological and pathological processes. Here, we summarize the importance of sulfation in the fields of oncology, virology, drug-induced liver injury (DILI), inflammatory bowel disease (IBD), and atherosclerosis. In oncology, sulfation is involved in tumor initiation, progression, and migration. In virology, sulfation influences viral entry, replication, and host immune response. In DILI, sulfation is associated with the incidence of DILI, where altered sulfation affects drug metabolism and toxicity. In IBD, dysregulation of sulfation compromises mucosal barrier and immune response. In atherosclerosis, sulfation influences the development of atherosclerosis by modulating the accumulation of lipoprotein, and the inflammation, proliferation, and migration of smooth muscle cells. The current review underscores the importance of further research to unravel the underlying mechanisms and therapeutic potential of targeting sulfoconjugation in various diseases. A better understanding of sulfation could facilitate the emergence of innovative diagnostic or therapeutic strategies.

Indexed as

AtherosclerosisInflammatory Bowel DiseasesGlycoproteinsHumansPeptidesGlycoproteinsPeptidesAtherosclerosisDrug-induced liver injuryGlycoproteinsInflammatory bowel diseaseOncologyProtein peptidesSulfoconjugationVirology

Identifiers

PMID37777160
PMCPMC10842354
OpenAlexW4387142864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.